Table 3.

Outcomes

	CTX (n = 64)	PCN G (n = 30)	P Value
Primary end point
Composite safety end point	9 (14.1)	8 (26.7)	.139
Secondary end points
Composite safety end point components
At least 1 readmission due to VGS or therapy	7 (10.9)	6 (20)	.336
Microbiological evidence of ESBL	1 (1.6)	1 (3)	.539
C. difficile infection	1 (1.6)	1 (3)	.539
Therapy modification or discontinuation due to adverse drug event	0 (0)	0 (0)	.549
Infection recurrence	0 (0)	0 (0)	N/A
Hospital readmission
At least 1 readmission in 6 mo	24 (37.5)	16 (53)	.148
No. of readmissions, median (IQR), d	0 (0–1)	1 (0–1.25)	.341
Time to first readmission, median (IQR), d	31 (15–60)	53 (29–91)	.135
All-cause mortality	0 (0)	2 (7)	.100

All data expressed as No. (%) unless otherwise noted.

Abbreviations: CTX, ceftriaxone; ESBL, extended-spectrum beta-lactamase; IQR, interquartile range; PCN G, penicillin G; VGS, viridans group streptococci.